Acadia Pharmaceuticals | ACAD - Ordinary Share Capital


Acadia Pharmaceuticals reported $171.09M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 171.09M 1.9M Mar/2026
ALKERMES USD 167.54M 1.08M Jun/2026
Alnylam Pharmaceuticals USD 133.73M 290K Jun/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.54M 267K Jun/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Cara Therapeutics USD 9.38M 2.01K Mar/2026
Corcept Therapeutics USD 107.33M 1.36M Mar/2026
Cytokinetics USD 124.43M 2.17M Mar/2026
Eisai JPY 282.46M 345K Jun/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
Incyte USD 200.98M 1.03M Jun/2026
J&J USD 2.41B 1.35M Mar/2026
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 100.55M 50K Jun/2026
Pfizer USD 5.7B 0 Jun/2026
Prothena USD 53.08M 756K Mar/2026
PTC Therapeutics USD 82.88M 1.41M Mar/2026
Sarepta Therapeutics USD 105.62M 53K Jun/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vanda Pharmaceuticals USD 58K 0 Dec/2024
Vertex Pharmaceuticals USD 253.3M 900K Jun/2026